Gene: POU2F3

25833
Epoc-1|OCT-11|OCT11|OTF-11|PLA-1|PLA1|Skn-1a
POU class 2 homeobox 3
protein-coding
11q23.3
Ensembl:ENSG00000137709 MIM:607394 Vega:OTTHUMG00000166140 UniprotKB:Q9UKI9
NG_030035.1
SNP Mapped
4   ANCO-SNPs
ND|AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.456e-2 (AD)  4.467e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs17245504chr11:120308044 (GRCh38.p7)T>Gnicotine dependenceSNV(Single Nucleotide Variation)
rs4142654chr11:120296348 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)
rs11603757chr11:120293949 (GRCh38.p7)G>Tnicotine dependenceSNV(Single Nucleotide Variation)
rs6589804chr11:120290932 (GRCh38.p7)G>Anicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ASF1B0.482
SLC4A10.475
RETN0.471
IFIT1B0.47
IL2RG0.466
RIPPLY10.46
TRIM100.452
RAB27A0.441
CASP80.441
PLEKHG20.439

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CRH-0.286
KIT-0.285
OR2L13-0.268
SLC32A1-0.265
DLX1-0.261
FSTL5-0.257
KCNC2-0.256
SPHKAP-0.254
VWC2-0.251
C16orf95-0.25

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in increased expression of POU2F3 mRNA"20453058
C0212962-ethoxyethanol2-ethoxyethanol results in increased expression of POU2F3 mRNA19643169
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU2F3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU2F3 mRNA"27188386
D020106AcrylamideAcrylamide results in decreased expression of POU2F3 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of POU2F3 gene28458013
D000643Ammonium ChlorideAmmonium Chloride affects the expression of POU2F3 mRNA16483693
C487081belinostatbelinostat results in increased expression of POU2F3 mRNA26272509
C487081belinostat"[NOG protein co-treated with belinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA"27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of POU2F3 mRNA15034205
C006780bisphenol Abisphenol A results in increased expression of POU2F3 mRNA17989879
C006780bisphenol Abisphenol A affects the methylation of POU2F3 promoter27334623
C006780bisphenol Abisphenol A results in decreased expression of POU2F3 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of POU2F3 gene28505145
C018021cobaltous chloridecobaltous chloride results in decreased expression of POU2F3 mRNA24612858
D003471CuprizoneCuprizone affects the expression of POU2F3 mRNA27523638
D004008DiclofenacDiclofenac results in increased expression of POU2F3 mRNA26934552
C118739entinostatentinostat results in increased expression of POU2F3 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA"27188386
C069837fullerene C60fullerene C60 results in decreased expression of POU2F3 mRNA19167457
C011890kojic acidkojic acid results in decreased expression of POU2F3 mRNA16595896
D008628MercuryMercury results in increased expression of POU2F3 mRNA16823088
C005219methyl cellosolvemethyl cellosolve results in increased expression of POU2F3 mRNA19643169
D009151Mustard GasMustard Gas results in decreased expression of POU2F3 mRNA15674843
D009151Mustard GasMustard Gas results in decreased expression of POU2F3 mRNA18988085
D009532NickelNickel results in decreased expression of POU2F3 mRNA24768652
C028007nickel monoxidenickel monoxide results in decreased expression of POU2F3 mRNA19167457
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of POU2F3 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of POU2F3 mRNA26272509
D010936Plant ExtractsPlant Extracts results in decreased expression of POU2F3 mRNA23557933
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of POU2F3 mRNA21570461|2405805
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of POU2F3 mRNA15034205
D014118Toxins, Biological"Toxins, Biological affects the expression of POU2F3 mRNA"19682533
C012589trichostatin Atrichostatin A results in increased expression of POU2F3 mRNA24935251
D014635Valproic AcidValproic Acid results in increased expression of POU2F3 mRNA23527032|2438349

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IMP12624109  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0001077transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IDA12624109  
GO:0001077transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IMP12624109  
GO:0005515protein binding-IPI12624109  
GO:0043565sequence-specific DNA binding-IDA9242494  
GO ID GO Term Qualifier Evidence PubMed
GO:0006357regulation of transcription by RNA polymerase II-TAS10473598  
GO:0006366transcription by RNA polymerase II-IEA-  
GO:0008544epidermis development-TAS10473598  
GO:0043922negative regulation by host of viral transcription-IDA14645924  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA12624109  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA9242494  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal